When the Orphan Drug Act passed, few resources existed to ease the difficult process of developing therapies for rare diseases. In 2001, Engage formed to fill the void and has since established expertise, tools and methods unique to the rare disease space. These expertise and methods have advanced therapies and increased access in over 100 rare disease areas.